Clinical Trial Update: BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports that BioGenCell's BGC101 (EnEPC) autologous cell therapy is being studied for critical limb ischemia in Phase 1/Phase 2 trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Arterial Disease
• Peripheral Vascular Disease

Drugs mentioned

• BGC101 (EnEPC) Autologous Cell Therapy

Snippet

Sponsor: BioGenCell Ltd. | Conditions: Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING